Evotec has appointed Rui Wang as the new Executive Vice President, Head of Global In Silico and AI, marking a significant step in enhancing its AI-driven research and development capabilities.
With over two decades of experience in the pharmaceutical and biotechnology sectors, Wang will lead efforts to integrate data analytics and AI throughout Evotec's R&D processes. His previous role at AstraZeneca involved overseeing data and AI initiatives, equipping him with the expertise to drive innovation at Evotec. The company's strategy emphasizes the importance of computational science in drug discovery and development, aiming to embed these tools within all operational aspects.
Dr. Christian Wojczewski, CEO of Evotec, highlighted Wang's role in fostering operational efficiency and innovation, indicating that advanced computational tools will be crucial for enhancing business segments, including Drug Discovery and Preclinical Development.
Wang underscored the necessity for companies to leverage the right data in AI-enabled drug discovery, positioning Evotec uniquely at the intersection of discovery and data. This appointment is expected to solidify Evotec's competitive advantage in the life sciences sector, particularly in areas such as oncology and immunology.